FATE News and Press, Fate Therapeutics Inc. From 07/07/21

Should Penny Stocks Be On Your List In 2021? Cancer stocks are some of the most popular among investors. Yes, we’re talking about companies in an industry working to tackle the second largest cause of death worldwide after cardiovascular disease. But we’re also talking...

Using the quarterly 13F filings, we extract 50 consensus stocks from 40 large hedge funds, each fund with more than $3.5 billion in assets under management. After the Q1-2021 13F filings, the consensus holdings are updated, 5 stocks were removed and 6 added from the universe now holdi...

Using the quarterly 13F filings, we extract 50 consensus stocks from 40 large hedge funds, each fund with more than $3.5 billion in assets under management. After the Q1-2021 13F filings, the consensus holdings are updated, 5 stocks were removed and 6 added from the universe now holdi...

Justin Sullivan/Getty Images News Today, Kite, a unit of Gilead ([[GILD]] -0.3%) and Shoreline Biosciences announced a partnership to develop novel cell therapies targeting cancer. As part of the deal, Shoreline is entitled to receive an upfront payment and $2.3B in additional payments. The c...

SAN DIEGO, June 15, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that Mark Plavsic, DVM, PhD, RAC has been appointed Chief Technical...

Lone Pine Capital’s 13F portfolio value increased marginally from $27.51B to $27.53B. The number of positions decreased from 41 to 38. They increased Facebook, Microsoft, and DoorDash while dropping DocuSign, Autodesk, and Humana. The top three positions are Shopify, Micros...

Fate Therapeutics is a pioneer in induced pluripotent stem cell research. They have been a research company mainly for nearly 15 years. Since last year, they have started producing clinical data, and the data is exciting. For further details see: Fate Therapeutics: Stron...

Using the quarterly 13F filings, we extract 50 consensus stocks from 40 large hedge funds, each fund with more than $3.5 billion Assets Under Management. After the Q1-2021 13F filings, the consensus holdings are updated, 5 stocks were removed and 6 added from the universe now holding ...

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants to invest in multiple biotech companies via one vehicle. The life science sector certainly holds a risk factor, and ETFs are a good wa...

Fate Therapeutics (FATE) highlights positive interim Phase 1 data from its FT516 program for patients with relapsed / refractory B-cell lymphoma at the 2021 American Society of Clinical Oncology ((ASCO)) Annual Meeting held virtually June 4-8, 2021. As of the data cutoff date of March 11, 202...